Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.

Marissa received B.S. degrees in Biology and Chemistry at the University of Denver and then earned her Ph.D. in Biochemistry at the University of Colorado Boulder. She joined Elion Labs in 2017 as a scientist, where she specialized in liquid chromatography and mass spectrometry analysis to support biotherapeutic primary structure and glycan characterization. Following the company’s acquisition by KBI Biopharma in 2019, Marissa progressed to a senior scientist role where she now manages a team of staff and leads product characterization studies that enable the commercialization of biological therapeutics.